|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
In two established animal models of PD, the PPARGC1A expression profiles differed from the profile in human PD in that the levels of CNS- and reference gene transcripts were decreased in several brain regions.
|
30236862 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We observed a dramatic increase in mitochondrial respiration, increased mitochondrial gene expression, and increased PGC-1α gene expression in PD cybrid cells expressing Ndi1.
|
30934776 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent findings have demonstrated that upregulation of PGC-1α expression in neurons can modulate MQC to prevent mitochondrial dysfunction in certain in vivo and in vitro aging or neurodegenerative encephalopathy models, such as Huntington's disease, Alzheimer's disease, and Parkinson's disease.
|
31410709 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181/SIRT1/PGC-1α/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells: Implication for association between chlorpyrifos and Parkinson's disease.
|
30835941 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In two established animal models of PD, the PPARGC1A expression profiles differed from the profile in human PD in that the levels of CNS- and reference gene transcripts were decreased in several brain regions.
|
30236862 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the mitochondrial respiratory function as detected by the mitochondrial oxygen consumption and the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and nuclear transcription factor 2 (NRF2) were reduced in the substantia nigra of PD rats, which were markedly reversed by fucoidan.
|
30090649 |
2018 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The genotype frequencies of PGC-1α-related gene variants were not associated with the risk of PD.
|
29496354 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, PGC-1α can be considered a potential therapeutic target for PD.
|
28611589 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, P2X7R and PGC-1α are potential targets in the treatment of PD.
|
28403913 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together these results suggest that the metformin-ATF2/CREB-PGC-1α pathway might be promising therapeutic target for PD.
|
28611284 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, we further showed that genetic or pharmacological activation of the Drosophila PGC-1α ortholog spargel is sufficient to rescue the disease phenotypes of Parkin and LRRK2 genetic fly models of PD, thus supporting the proposed use of PGC-1α-related strategies for neuroprotection in PD.
|
28407521 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data indicate that restoration of PGC-1α is a promising approach for development of effective drugs for the treatment of PD and related synucleinopathies.
|
25363075 |
2015 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, our results highlight an important role for PGC-1α in controlling the mitochondrial function of nigral neurons accumulating α-synuclein, which may be critical for gender-dependent vulnerability to Parkinson's disease.
|
25853296 |
2015 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although ZNF746, also known as Parkin-interacting substrate (PARIS), has been reported to suppress peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and its target gene NRF-1 leading to the neurodegeneration in Parkinson's disease, its function in tumorigenesis has yet to be investigated.
|
24145959 |
2014 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several single-nucleotide polymorphisms (SNPs) located in two separate haplotype blocks of PPARGC1A have shown associations with Huntington's disease (HD) and Parkinson's disease, but causative SNPs have not been identified.
|
22589246 |
2012 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Within the last year, studies of Parkinson's disease, another involuntary movement disorder long associated with mitochondrial dysfunction, have shown that PGC-1α dysregulation is contributing to its pathogenesis.
|
22100502 |
2012 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Relationships among PGC-1α and its downstream targets NRF1 and TFAM were very similar in PD and CTL and were related to mitochondrial NADH-driven electron flow.
|
23939409 |
2012 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data confirm the role of parkin in mitochondrial homeostasis and suggest a potential involvement of the PGC-1α pathway in the pathogenesis of Parkinson's disease.
|
21215313 |
2011 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The rs8192678 PGC-1α SNP was not associated with the risk of PD.
|
21595954 |
2011 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present review provides an overview of the advances in the understanding of the role of the PGC-1α system in HD pathogenesis and explores the implications for ALS, AD and PD.
|
20840068 |
2010 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our systems biology analysis of Parkinson's disease identifies PGC-1α as a potential therapeutic target for early intervention.
|
20926834 |
2010 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exposure of PD but not control cybrid cells to MTD-TFAM protein alone or MTD-TFAM + mtDNA complex increased expression of PGC-1alpha, suggesting activation of mitochondrial biogenesis.
|
19374590 |
2009 |